Scholarlink

Background <p>The anatomical and pathophysiological characteristics of coronary artery disease vary between the sexes. This study investigated the impact of sex on outcomes in patients with de novo coronary artery lesions treated with drug-coated balloons (DCB) or drug-eluting stents (DES).</p> Methods <p>REC-CAGEFREE I was an investigator-initiated, non-inferiority trial conducted at 43 sites in China from Feb 5, 2021, to May 1, 2022, which randomized 2,272 patients for treating de novo coronary lesions, regardless of vessel diameter. After successful lesion pre-dilatation, eligible patients were randomized (1:1) to either DCB angioplasty with the option of rescue stenting or intended DES deployment. In this prespecified subgroup analysis, patients were analyzed by sex based on their medical records. The primary endpoint was device-oriented composite endpoint (DoCE), including cardiovascular death, target-vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization at 2&#xa0;years. Between-group differences were compared by Cox proportional-hazards models, and imbalances in baseline characteristics were adjusted with inverse probability of treatment weighting (IPTW). The analyses were conducted in the intention-to-treat population.</p> Results <p>A total of 2,272 participants underwent randomization, of which 698 (30.7%) were female and 1,574 (69.3%) were male. At 2 years, no statistically significant differences in the incidence of DoCE were observed between sexes (36 [5.2%] for females and 74 [4.7%] for males, HR<sub>IPTW</sub>:1.04, 95%CI:0.67 to 1.61, <i>P</i> = 0.877). Compared with DES, DCB was associated with a numerically higher risk of DoCE in females (6.3% versus 3.9%, HR<sub>IPTW</sub>:1.55, 95%CI:0.78 to 3.11, <i>P</i> = 0.210) and a statistically significant higher risk in males (6.4% versus 3.1%, HR<sub>IPTW</sub>:2.28, 95%CI:1.40 to 3.70, <i>P</i> = 0.001), respectively, with no significant sex-by-treatment (DCB/DES) interaction observed (<i>P</i><sub>interaction</sub> = 0.575). The prognosis of DCB and DES differed significantly between small vessel disease (SVD) and non-SVD among females (<i>P</i><sub>interaction</sub> = 0.007), but not among males (<i>P</i><sub>interaction</sub> = 0.408).</p> Conclusions <p>For patients with de novo, non-complex coronary artery disease, DCB was associated with a significantly higher risk of 2-year DoCE compared with DES in males, whereas a consistent but non-significant trend was observed in females.</p> Trial registration <p>ClinicalTrials.gov identifier: NCT04561739.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of sex on outcomes in patients treated with drug-coated balloons versus drug-eluting stents for de novo coronary artery lesions: Insights from the REC-CAGEFREE I trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月22日

查看全文
  • Ping Wang,
  • Jingyu Zhou,
  • Haokao Gao,
  • Tao Hu,
  • Dongdong Sun,
  • Qiong Wang,
  • Hong Jiang,
  • Zhiyong Yin,
  • Shangyu Wen,
  • Yuanzhe Jin,
  • Hui Chen,
  • Ming Yuan,
  • Lin Zhong,
  • Sigan Hu,
  • Zhexun Lian,
  • Zhiwei Jiang,
  • Jielai Xia,
  • Jianzheng Liu,
  • Guotao Fu,
  • Xingqiang He,
  • Bin Zhu,
  • Scot Garg,
  • Yoshinobu Onuma,
  • Duolao Wang,
  • Patrick W. Serruys,
  • Chao Gao,
  • Ling Tao

摘要

Background

The anatomical and pathophysiological characteristics of coronary artery disease vary between the sexes. This study investigated the impact of sex on outcomes in patients with de novo coronary artery lesions treated with drug-coated balloons (DCB) or drug-eluting stents (DES).

Methods

REC-CAGEFREE I was an investigator-initiated, non-inferiority trial conducted at 43 sites in China from Feb 5, 2021, to May 1, 2022, which randomized 2,272 patients for treating de novo coronary lesions, regardless of vessel diameter. After successful lesion pre-dilatation, eligible patients were randomized (1:1) to either DCB angioplasty with the option of rescue stenting or intended DES deployment. In this prespecified subgroup analysis, patients were analyzed by sex based on their medical records. The primary endpoint was device-oriented composite endpoint (DoCE), including cardiovascular death, target-vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization at 2 years. Between-group differences were compared by Cox proportional-hazards models, and imbalances in baseline characteristics were adjusted with inverse probability of treatment weighting (IPTW). The analyses were conducted in the intention-to-treat population.

Results

A total of 2,272 participants underwent randomization, of which 698 (30.7%) were female and 1,574 (69.3%) were male. At 2 years, no statistically significant differences in the incidence of DoCE were observed between sexes (36 [5.2%] for females and 74 [4.7%] for males, HRIPTW:1.04, 95%CI:0.67 to 1.61, P = 0.877). Compared with DES, DCB was associated with a numerically higher risk of DoCE in females (6.3% versus 3.9%, HRIPTW:1.55, 95%CI:0.78 to 3.11, P = 0.210) and a statistically significant higher risk in males (6.4% versus 3.1%, HRIPTW:2.28, 95%CI:1.40 to 3.70, P = 0.001), respectively, with no significant sex-by-treatment (DCB/DES) interaction observed (Pinteraction = 0.575). The prognosis of DCB and DES differed significantly between small vessel disease (SVD) and non-SVD among females (Pinteraction = 0.007), but not among males (Pinteraction = 0.408).

Conclusions

For patients with de novo, non-complex coronary artery disease, DCB was associated with a significantly higher risk of 2-year DoCE compared with DES in males, whereas a consistent but non-significant trend was observed in females.

Trial registration

ClinicalTrials.gov identifier: NCT04561739.